Linked CD4(+)/CD8(+) T cell neoantigen vaccination overcomes immune checkpoint blockade resistance and enables tumor regression

Therapeutic benefit to immune checkpoint blockade (ICB) is currently limited to the subset of cancers thought to possess a sufficient tumor mutational burden (TMB) to allow for the spontaneous recognition of neoantigens (NeoAg) by autologous T cells. We explored whether the response to ICB of an agg...

Descripción completa

Detalles Bibliográficos
Autores principales: Dolina, Joseph S., Lee, Joey, Brightman, Spencer E., McArdle, Sara, Hall, Samantha M., Thota, Rukman R., Zavala, Karla S., Lanka, Manasa, Ramamoorthy Premlal, Ashmitaa Logandha, Greenbaum, Jason A., Cohen, Ezra E. W., Peters, Bjoern, Schoenberger, Stephen P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10471175/
https://www.ncbi.nlm.nih.gov/pubmed/37655661
http://dx.doi.org/10.1172/JCI164258

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10471175/
https://www.ncbi.nlm.nih.gov/pubmed/37655661
http://dx.doi.org/10.1172/JCI164258

Ejemplares similares